NCT05320588View on ClinicalTrials.gov

A Study in Patients With Advanced Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2027

Conditions
Advanced CancerAdvanced Solid TumorCancerOncology
Interventions
DRUG

BIO-106

BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)

DRUG

Pembrolizumab

Programmed death receptor-1 (PD 1)-blocking antibody

Trial Locations (3)

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

78758

RECRUITING

NEXT Oncology Austin, Austin

Sponsors
All Listed Sponsors
lead

BiOneCure Therapeutics Inc.

INDUSTRY